Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers

BACKGROUND AND OBJECTIVE: Tucatinib is approved for treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. Understanding potential drug–drug interactions (DDIs) informs proper dosing when co-administering tucatinib with other therapies. The aim of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Topletz-Erickson, Ariel, Lee, Anthony, Rustia, Evelyn L., Sun, Hao, Mayor, JoAl G., Abdulrasool, Layth I., Walker, Luke, Endres, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553805/
https://www.ncbi.nlm.nih.gov/pubmed/35931943
http://dx.doi.org/10.1007/s40262-022-01144-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553805/
https://www.ncbi.nlm.nih.gov/pubmed/35931943
http://dx.doi.org/10.1007/s40262-022-01144-z

Ejemplares similares